Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan

Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.o.c

National Yang Ming Chiao Tung University

Mao-Chi Weng

Chien-Chung Hsia

Wuu-Jyh Lin

Mei-Hui Wang

Kun-Liang Lin

Hsin-Ell Wang

Hao-Wen Kao

Chao-Cheng Chen

Kwan-Hwa Chi

Der-Chi Tien

Po-Jung Chen

Hung-Man Yu

Chia-Yu Hu

Jyun-Hong Chen

Chun-Hung Yang

The present invention relates to a hydroxamic acid-based contrast agent containing an isotope of fluorine, which comprises a compound having a structure of Formula (III):  wherein Rrepresents radioactive fluorine-18 (F) or isotope fluorine-19 (F), and Rrepresents hydroxyamine &#x2014;(NH)OH. The hydroxamic acid-based contrast agent containing an isotope of fluorine provided in the present invention has the capability of selectively inhibiting histone deacetylase (HDAC) subtypes 8/6/3, and specifically targets to the focus of spinocerebellar ataxia with over-activation of HDAC. By labeling with the radioisotope fluorine-18, a positron emission tomography (PET) image is obtained with the hydroxamic acid-based contrast agent containing radioisotope fluorine-18, whereby spinocerebellar ataxia is effectively detected. Therefore, the hydroxamic acid-based contrast agent containing an isotope of fluorine provided in the present invention is potentially useful as a probe for early diagnosis and evaluation of the therapeutic effect of spinocerebellar ataxia.

Hydroxamic acid type contrast agent containing radioisotope fluoride, preparation method and application thereof

The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof. The above-mentioned pharmaceutical composition is applied to evaluate a tumor accumulation time, so as to establish the optimal policy for a radiofrequency- or laser-induced thermal adjuvant therapy for tumors.

Radiolabeled active targeting pharmaceutical composition and the use thereof

Disclosed herein are a novel polymer, a thermosensitive carrier prepared using the same and use thereof. The novel polymer is essentially composed of a PEO-PPO-PEO block copolymer and silane.

Polymer, thermosensitive carrier and use thereof

Growing community of inventors

Taoyuan County, Taiwan

Mao-Chi Weng